
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Quince Therapeutics, Inc., is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. The company's Phase 3 lead asset, EryDex, is the first product in development that leverages its proprietary Autologous Intracellular Drug ... Quince Therapeutics, Inc., is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. The company's Phase 3 lead asset, EryDex, is the first product in development that leverages its proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform, which is a novel drug/device combination that uses an automated process designed to encapsulate a drug into the patient's own red blood cells. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.19 | 14.0740740741 | 1.35 | 1.56 | 1.33 | 69784 | 1.44862923 | CS |
4 | -0.15 | -8.87573964497 | 1.69 | 1.69 | 1.28 | 98972 | 1.43676716 | CS |
12 | -0.485 | -23.950617284 | 2.025 | 2.07 | 1.28 | 126314 | 1.67877888 | CS |
26 | 0.842501 | 120.788847009 | 0.697499 | 2.45 | 0.675 | 347723 | 1.43773074 | CS |
52 | 0.32 | 26.2295081967 | 1.22 | 2.45 | 0.5116 | 236112 | 1.24618629 | CS |
156 | -2.78 | -64.3518518519 | 4.32 | 6.8 | 0.5116 | 414034 | 1.58431705 | CS |
260 | -40.75 | -96.3584771814 | 42.29 | 121.98 | 0.5116 | 457748 | 12.80185857 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions